Since the first AIDS cases were reported in 1981, finding an HIV vaccine has been challenging due to the virus’s rapid mutation and numerous strains. Unlike most viruses, HIV overwhelms the immune system’s ability to produce effective antibodies. However, some HIV patients develop broadly neutralizing antibodies (bNAbs) that can target many strains. Recent research has made progress in stimulating these bNAbs using novel vaccines. These vaccines, tested successfully in animals, aim to guide the immune system to produce bNAbs. While promising, further research is needed to confirm their effectiveness in humans.